From Crispr Therapeutics's results release of 2026年11月2日; its quarterly report has since been filed.

• Revenue

  Actual

  $12.7M

  +24% q/q ↑

  Guided

  —

  No guide given

• EPS, GAAP

  Actual

  -$1.15

  Guided

  —

  No guide given

• Operating income, GAAP

  Actual

  -$130M

  Guided

  —

  No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.